Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ikram Mezghiche, Hanane Yahia-Cherbal, Lars Rogge & Elisabetta Bianchi. (2021) Novel approaches to develop biomarkers predicting treatment responses to TNF-blockers. Expert Review of Clinical Immunology 17:4, pages 331-354.
Read now
Read now
Samuele Naviglio, Paolo Giuffrida, Gabriele Stocco, Marco Vincenzo Lenti, Alessandro Ventura, Gino Roberto Corazza & Antonio Di Sabatino. (2018) How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 12:8, pages 797-810.
Read now
Read now
Yu Nishida, Shuhei Hosomi, Kenji Watanabe, Kimihiko Watanabe, Tomomi Yukawa, Koji Otani, Yasuaki Nagami, Fumio Tanaka, Koichi Taira, Noriko Kamata, Hirokazu Yamagami, Tetsuya Tanigawa, Toshio Watanabe & Yasuhiro Fujiwara. (2018) Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scandinavian Journal of Gastroenterology 53:5, pages 579-585.
Read now
Read now
Thomas Billiet, Isabelle Cleynen, Vera Ballet, Karolien Claes, Fred Princen, Sharat Singh, Marc Ferrante, Gert Van Assche, Ann Gils & Severine Vermeire. (2017) Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn’s disease. Scandinavian Journal of Gastroenterology 52:10, pages 1086-1092.
Read now
Read now
Articles from other publishers (29)
Nuno Vale, Mariana Pereira & Rui Amaral Mendes. (2023) Systemic Inflammatory Disorders, Immunosuppressive Treatment and Increase Risk of Head and Neck Cancers—A Narrative Review of Potential Physiopathological and Biological Mechanisms. Cells 12:17, pages 2192.
Crossref
Crossref
Xinhui Yang, Jintong Shi, Gaoyang Wang, Huifang Chen, Youqiong Ye, Jie Zhong & Zhengting Wang. (2023) Novel mRNA Signature for Anti-TNF-α Therapy Primary Response in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases 29:9, pages 1458-1469.
Crossref
Crossref
Liang-Fang Wang, Ping-Run Chen, Si-Ke He, Shi-Hao Duan & Yan Zhang. (2023) Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World Journal of Gastroenterology 29:29, pages 4481-4498.
Crossref
Crossref
Liliana Lykowska-Szuber, Michal Walczak, Agnieszka Dobrowolska & Marzena Skrzypczak-Zielinska. (2023) Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn’s disease patients. European Journal of Gastroenterology & Hepatology.
Crossref
Crossref
Marco Vincenzo Lenti, Maria Lia Scribano, Livia Biancone, Rachele Ciccocioppo, Daniela Pugliese, Luca Pastorelli, Gionata Fiorino, Edoardo Savarino, Flavio Andrea Caprioli, Sandro Ardizzone, Massimo Claudio Fantini, Gian Eugenio Tontini, Ambrogio Orlando, Gianluca Matteo Sampietro, Giacomo Carlo Sturniolo, Giovanni Monteleone, Maurizio Vecchi, Anna Kohn, Marco Daperno, Renata D’Incà, Gino Roberto Corazza & Antonio Di Sabatino. (2023) Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease. Frontiers in Medicine 10.
Crossref
Crossref
Sophie Vieujean & Edouard Louis. (2023) Precision medicine and drug optimization in adult inflammatory bowel disease patients. Therapeutic Advances in Gastroenterology 16, pages 175628482311733.
Crossref
Crossref
Hiroshi Nakase, Noriko Sato, Naomi Mizuno & Yoshiko Ikawa. (2022) The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmunity Reviews 21:3, pages 103017.
Crossref
Crossref
Marco Gasparetto, Caterina Strisciuglio, Amit Assa, Kostantinos Gerasimidis, Federica Giachero, Jan Novak, Philip Robinson, Bálint Tél, Matthias ZilbauerAndreas Jenke. (2022) Making Research Flourish Through ESPGHAN: A Position Paper From the ESPGHAN Special Interest Group for Basic and Translational Research. Journal of Pediatric Gastroenterology & Nutrition 74:2, pages 301-312.
Crossref
Crossref
Run-Feng Zhang, Shuang Liu, Yun-Wei WangJi Li. (2021) Potential molecular biomarkers used to predict the response to biological therapies in ulcerative colitis. Chinese Medical Journal 134:9, pages 1058-1060.
Crossref
Crossref
Liliana Lykowska-Szuber, Michal Walczak, Marzena Skrzypczak-Zielinska, Joanna Suszynska-Zajczyk, Kamila Stawczyk-Eder, Katarzyna Waszak, Piotr Eder, Anna Wozniak, Iwona Krela-Kazmierczak, Ryszard Slomski & Agnieszka Dobrowolska. (2021) Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease. Frontiers in Immunology 12.
Crossref
Crossref
Martina Franzin, Katja Stefančič, Marianna Lucafò, Giuliana Decorti & Gabriele Stocco. (2021) Microbiota and Drug Response in Inflammatory Bowel Disease. Pathogens 10:2, pages 211.
Crossref
Crossref
Michal Walczak, Liliana Lykowska-Szuber, Marianna Plucinska, Kamila Stawczyk-Eder, Oliwia Zakerska-Banaszak, Piotr Eder, Iwona Krela-Kazmierczak, Michal Michalak, Marek Zywicki, Wojciech M. Karlowski, Marlena Szalata, Agnieszka Dobrowolska, Ryszard Slomski & Marzena Skrzypczak-Zielinska. (2020) Is Polymorphism in the Apoptosis and Inflammatory Pathway Genes Associated With a Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients?. Frontiers in Pharmacology 11.
Crossref
Crossref
Mitchell R. K. L. Lie, Emma Paulides & C. Janneke van der Woude. (2020) Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. International Journal of Colorectal Disease 35:8, pages 1489-1500.
Crossref
Crossref
Lorenzo Bertani, Laura Baglietto, Luca Antonioli, Matteo Fornai, Gherardo Tapete, Eleonora Albano, Linda Ceccarelli, Maria Gloria Mumolo, Carolina Pellegrini, Ersilia Lucenteforte, Nicola de Bortoli, Massimo Bellini, Santino Marchi, Corrado Blandizzi & Francesco Costa. (2020) Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. British Journal of Clinical Pharmacology 86:7, pages 1296-1305.
Crossref
Crossref
Javier P Gisbert & María Chaparro. (2020) Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 14:5, pages 694-709.
Crossref
Crossref
Bahez Gareb, Antonius T. Otten, Henderik W. Frijlink, Gerard Dijkstra & Jos G. W. Kosterink. (2020) Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 12:6, pages 539.
Crossref
Crossref
Lorenzo Bertani, Luca Antonioli, Matteo Fornai, Gherardo Tapete, Giovanni Baiano Svizzero, Santino Marchi, Corrado Blandizzi & Francesco Costa. (2020) Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. Minerva Gastroenterologica e Dietologica 65:4.
Crossref
Crossref
Margarita L. Martinez-Fierro, Idalia Garza-Veloz, Maria R. Rocha-Pizaña, Edith Cardenas-Vargas, Miguel A. Cid-Baez, Fabiola Trejo-VazquezVirginia Flores-Morales, Gabriela A. Villela-Ramirez, Ivan Delgado-Enciso, Iram P. Rodriguez-SanchezYolanda Ortiz-Castro. (2019) Serum cytokine, chemokine, and growth factor profiles and their modulation in inflammatory bowel disease. Medicine 98:38, pages e17208.
Crossref
Crossref
Koji Kimura, Atsushi Yoshida, Fumihiko Katagiri, Risa Takayanagi & Yasuhiko Yamada. (2019) Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. Biopharmaceutics & Drug Disposition 40:7, pages 250-261.
Crossref
Crossref
Heike Schmitt, Ulrike Billmeier, Walburga Dieterich, Timo Rath, Sophia Sonnewald, Stephen Reid, Simon Hirschmann, Kai Hildner, Maximilian J Waldner, Jonas Mudter, Arndt Hartmann, Robert Grützmann, Clemens Neufert, Tino Münster, Markus F Neurath & Raja Atreya. (2019) Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease. Gut 68:5, pages 814-828.
Crossref
Crossref
Igor Vladimirovich Obraztsov, Katerina Evgenievna Shirokikh, Olga Isaakovna Obraztsova, Marina Vladimirovna Shapina, Ming-Hsi Wang & Igor Lvovich Khalif. (2019) Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients. Inflammatory Bowel Diseases 25:3, pages 524-531.
Crossref
Crossref
Matthew C. Choy, Dean Seah & Peter De Cruz. 2019. Biomarkers in Inflammatory Bowel Diseases. Biomarkers in Inflammatory Bowel Diseases
121
130
.
Toer W. Stevens, Mijntje Matheeuwsen, Maria H. Lönnkvist, Claire E. Parker, Manon E. Wildenberg, Krisztina B. Gecse & Geert R. D’Haens. (2018) Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease—personalised medicine in its infancy. Alimentary Pharmacology & Therapeutics 48:11-12, pages 1213-1231.
Crossref
Crossref
Christoffer Soendergaard, Jakob Benedict Seidelin, Casper Steenholdt & Ole Haagen Nielsen. (2018) Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterology 5:1, pages e000208.
Crossref
Crossref
John Gubatan, Shuji Mitsuhashi, Maria Serena Longhi, Talia Zenlea, Laura Rosenberg, Simon Robson & Alan C. Moss. (2018) Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis. Cytokine 103, pages 38-45.
Crossref
Crossref
Lauren Beswick, Bei Ye & Daniel R. van Langenberg. (2016) Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis. Inflammatory Bowel Diseases 22:12, pages 2966-2976.
Crossref
Crossref
Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov & Mark A. Ainsworth. (2016) Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflammatory Bowel Diseases 22:8, pages 1999-2015.
Crossref
Crossref
Maria K. Magnusson, Hans Strid, Maria Sapnara, Anders Lasson, Antal Bajor, Kjell-Arne Ung & Lena ?hman. (2016) Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition. Journal of Crohn's and Colitis 10:8, pages 943-952.
Crossref
Crossref
Heba Abdel-Aziz, Walaa Wadie, Olaf Scherner, Thomas Efferth & Mohamed T. Khayyal. (2015) Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease. Journal of Natural Products 78:6, pages 1309-1315.
Crossref
Crossref